Market closed
Repligen/$RGEN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Repligen
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Ticker
$RGEN
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
-
Website
Repligen Metrics
BasicAdvanced
$8.1B
Market cap
-
P/E ratio
-$0.04
EPS
0.96
Beta
-
Dividend rate
Price and volume
Market cap
$8.1B
Beta
0.96
52-week high
$211.13
52-week low
$113.50
Average daily volume
685K
Financial strength
Current ratio
10.442
Quick ratio
8.425
Long term debt to equity
32.742
Total debt to equity
37.398
Interest coverage (TTM)
1.20%
Management effectiveness
Return on assets (TTM)
0.60%
Return on equity (TTM)
-0.40%
Valuation
Price to revenue (TTM)
12.614
Price to book
4.01
Price to tangible book (TTM)
12.48
Price to free cash flow (TTM)
61.497
Growth
Revenue change (TTM)
-4.46%
Earnings per share change (TTM)
-101.86%
3-year revenue growth (CAGR)
2.59%
3-year earnings per share growth (CAGR)
-73.79%
What the Analysts think about Repligen
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Repligen stock.
Repligen Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Repligen Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Repligen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Repligen stock?
Repligen (RGEN) has a market cap of $8.1B as of December 22, 2024.
What is the P/E ratio for Repligen stock?
The price to earnings (P/E) ratio for Repligen (RGEN) stock is 0 as of December 22, 2024.
Does Repligen stock pay dividends?
No, Repligen (RGEN) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Repligen dividend payment date?
Repligen (RGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Repligen?
Repligen (RGEN) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.